GoAI
Get started
908 Devices Inc. logo

908 Devices Inc.

MASS

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$10.68

+$0.33 · +3.19%

Aug 21, 4:00 PM ET

MASS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

53

Fair Value

Momentum

55

Neutral

Sentiment

49

Mixed

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Kevin J. Knopp
Listed since
Dec 18, 2020
Employees
172

Market position

Day range

Current $10.68

52-week range

Current $10.68

Open
$10.425
Previous close
$10.35
Volume
528.31K
1.58× average
Average volume
334.16K
Average daily volume
Market cap
438.17M USD
Beta
0.63
Market reference 1
50-day average
$8.5226
+25.31% above average
200-day average
$7.0792
+50.86% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
93.88M USD
P/E (TTM)
-11.48×
P/B (TTM)
3.18×
P/S (TTM)
7.2×
EV / EBITDA
-3.25×
Earnings yield
-19.27%
Free cash flow yield
-12.96%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
49.79%
Operating margin
-46.01%
Net margin
-56.68%
Return on equity
-25.50%
Return on assets
-19.28%
Return on invested capital
-13.97%

Financial health

Debt / equity
0.03×
Current ratio
4.24×
Altman Z-score
2.2
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends74%0%-73%-147%Gross margin, FY2021: 55.05%Gross margin, FY2022: 55.54%Gross margin, FY2023: 50.41%Gross margin, FY2024: 50.18%Gross margin, FY2025: 47.68%Operating margin, FY2021: -52.29%Operating margin, FY2022: -75.52%Operating margin, FY2023: -85.13%Operating margin, FY2024: -128.65%Operating margin, FY2025: -43.03%Net margin, FY2021: -52.53%Net margin, FY2022: -71.64%Net margin, FY2023: -72.47%Net margin, FY2024: -121.09%Net margin, FY2025: -65.20%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 55.05%. Gross margin FY2022 55.54%. Gross margin FY2023 50.41%. Gross margin FY2024 50.18%. Gross margin FY2025 47.68%. Operating margin FY2021 -52.29%. Operating margin FY2022 -75.52%. Operating margin FY2023 -85.13%. Operating margin FY2024 -128.65%. Operating margin FY2025 -43.03%. Net margin FY2021 -52.53%. Net margin FY2022 -71.64%. Net margin FY2023 -72.47%. Net margin FY2024 -121.09%. Net margin FY2025 -65.20%.

Income trends

Revenue

56.2M USD-5.76%

Operating income

−24.18M USD+68.48%

Net income

−36.64M USD+49.26%
Income trends across reported periods73.27M USD18.73M USD−35.81M USD−90.35M USDRevenue, FY2021: 42.21M USDRevenue, FY2022: 46.85M USDRevenue, FY2023: 50.23M USDRevenue, FY2024: 59.63M USDRevenue, FY2025: 56.2M USDOperating income, FY2021: −22.07M USDOperating income, FY2022: −35.38M USDOperating income, FY2023: −42.76M USDOperating income, FY2024: −76.72M USDOperating income, FY2025: −24.18M USDNet income, FY2021: −22.17M USDNet income, FY2022: −33.56M USDNet income, FY2023: −36.4M USDNet income, FY2024: −72.21M USDNet income, FY2025: −36.64M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 42.21M USD. Revenue FY2022 46.85M USD. Revenue FY2023 50.23M USD. Revenue FY2024 59.63M USD. Revenue FY2025 56.2M USD. Operating income FY2021 −22.07M USD. Operating income FY2022 −35.38M USD. Operating income FY2023 −42.76M USD. Operating income FY2024 −76.72M USD. Operating income FY2025 −24.18M USD. Net income FY2021 −22.17M USD. Net income FY2022 −33.56M USD. Net income FY2023 −36.4M USD. Net income FY2024 −72.21M USD. Net income FY2025 −36.64M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue56.2M USD59.63M USD50.23M USD46.85M USD42.21M USD
Cost of goods sold29.4M USD29.71M USD24.91M USD20.83M USD18.97M USD
Gross profit26.8M USD29.93M USD25.32M USD26.02M USD23.23M USD
Research and development13.8M USD25.5M USD21.9M USD17.53M USD13.07M USD
Selling, general, and administrative37.18M USD——43.88M USD32.24M USD
Operating expenses50.98M USD106.64M USD68.08M USD61.41M USD45.3M USD
Interest income4.14M USD4.49M USD6.48M USD2.03M USD548K USD
Interest expense——201K USD129K USD486K USD
Depreciation and amortization4.47M USD4.68M USD2.38M USD1.61M USD925K USD
Operating income−24.18M USD−76.72M USD−42.76M USD−35.38M USD−22.07M USD
Net income−36.64M USD−72.21M USD−36.4M USD−33.56M USD−22.17M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
-14.62%
11 comparable reports
Latest EPS result
-0.11
Estimate -0.14 · Beat by 22.54%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.04-0.23-0.41-0.6Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual -0.56, estimate -0.35, surprise -60.00%, Miss. Q2 2025, reported May 13, 2025: actual -0.22, estimate -0.27, surprise +18.52%, Beat. Q3 2025, reported Aug 5, 2025: actual -0.36, estimate -0.16, surprise -125.00%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.15, estimate -0.115, surprise -30.43%, Miss. Q1 2026, reported Mar 3, 2026: actual -0.05, estimate -0.06, surprise +16.67%, Beat. Q2 2026, reported May 6, 2026: actual -0.22, estimate -0.15, surprise -46.67%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.11, estimate -0.142, surprise +22.54%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.16, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates19.57M16.61M13.64M10.68MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 18.82M USD, estimate 16.71M USD, surprise +12.65%, Beat. Q2 2025, reported May 13, 2025: actual 11.8M USD, estimate 11.43M USD, surprise +3.21%, Beat. Q3 2025, reported Aug 5, 2025: actual 13.04M USD, estimate 12.17M USD, surprise +7.13%, Beat. Q4 2025, reported Nov 10, 2025: actual 14.01M USD, estimate 13.52M USD, surprise +3.56%, Beat. Q1 2026, reported Mar 3, 2026: actual 17.38M USD, estimate 15.84M USD, surprise +9.70%, Beat. Q2 2026, reported May 6, 2026: actual 13.38M USD, estimate 13.16M USD, surprise +1.67%, Beat. Q3 2026, reported Aug 11, 2026: actual 16.07M USD, estimate 15.37M USD, surprise +4.55%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 18.57M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$12.00

12.36% upside
Past 12 months12-month forecastHigh $12.00Average $12.00Low $12.00

Rating distribution

6 ratings
Strong buy00%
Buy6100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

4 institutions
Roth CapitalmaintainBuy

MASS news

gurufocus.com

Is 908 Devices Inc (MASS) Overvalued After 3.3% Rally? GF Value Says Overvalued

On August 21, 2026, 908 Devices Inc (MASS) shares rose 3.3% to $10.68, marking a notable increase within its 52-week range of $5.03 to $10.70. The stock has sho

Read source
marketbeat.com

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15…

Read source
marketbeat.com

908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market

908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line,…

Read source
seekingalpha.com

908 Devices Q2: Another Solid Report

908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%.…

Read source
seekingalpha.com

908 Devices: Mission Critical Devices Drive Growth

908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and…

Read source
businesswire.com

908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications,…

Read source

MASS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MASS

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
21.18M
Weight
1.02%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$49.45+3.80%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
7.72M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.37M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
7.05M
Weight
0.02%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.72M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.69M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.54M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.31M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research MASS

research.disclaimer